Detection and significance of occult axillary metastatic disease in breast cancer patients

Breast Journal

Volumn 5, Issue 4, 1999, Pages 221-229

  Siziopikou, Kalliopi P ^a   Schnitt, Stuart J ^b   Connolly, James L ^b   Hayes, Daniel F ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Axillary lymph nodes; Breast cancer; Immunohistochemistry; Micrometastases; Sentinel node

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; REVIEW;

EID: 0032841964     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1999.99053.x     Document Type: Review

References (64)

1. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
2. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326:1756-61.
3. Fisher B, Bauer M, Wickerham DL. Relationship of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983;52:1551-57.
4. Fisher ER, Sass E, Fisher B. Pathological findings from the NSABP protocol 4: discriminates for tenth year treatment failure. Cancer 1984;53:712-23.
5. Henderson C. Adjuvant systemic therapy: state of the art. Breast Cancer Res Treat 1989;14:3-22.
6. Ludwig Breast Cancer Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320: 491-96.
7. Harris JR, Hellman S. Natural history of breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases. Philadelphia: J.B. Lippincott, 1991:165-206.
8. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06; 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71:2507-14.
9. Saphir O, Amromin GD. Obscure axillary lymph-node metastasis in carcinoma of the breast. Cancer 1948;1:238-41.
10. Pickren JW. Significance of occult metastases; a study of breast cases. Cancer 1961;14:1266-71.
11. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
12. Wilkinson EJ, Hause LL, Kuzma JF, et al. Occult axillary lymph node metastasis in patients with invasive breast carcinoma. Lab Invest 1983;44:83A.
13. Friedman S, Bertin F, Mouriesse H, et al. Importance of tumor cells in axillary node sinus margins ("clandestine" metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol 1988;5:483-87.
14. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-68.
15. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523-27.
16. Sloane JP, Ormerod MG, Impie SF, Coombes RC. The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer 1980;42: 392-98.
17. Wells CA, Heryet A, Brochier J, Gatter KC, Mason DY. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50:193-97.
18. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immuno-histochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986;54:631-36.
19. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
20. Sedmak DD, Meineke TA, Knechtges DS. Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins. Arch Pathol Lab Med 1989;113:786-89.
21. Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989-2:516-20.
22. Chen Z, Wen D, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology. Dis Markers 1991;9: 239-48.
23. Galea MH, Athanassiou E, Bell J, et al. Occult regional lymph node metastases from breast carcinoma: immunohistochemical detection with antibodies CAM 5.2 and NCRC-11. J Pathol 1991;165:221-27.
24. Byrne J, Horgan PG, England S, Callaghan J, Given HF. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur J Cancer 1992;28:658-60.
25. Cote R, Chainwun B, Qu J, et al. Prognostic importance of occult lymph node metastases in patients with breast cancer. Proc Annu Meet Am Assoc Cancer Res 1992;33:202.
26. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459-63.
27. Nasser IA, Lee AK, Bosari S, Saganich R, Heatly G, Silverman ML. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993;24:950-57.
28. Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54:2986-90.
29. Noguchi S, Aihara T, Nakamori S, et al. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994;74:1595-600.
30. Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55:3417-20.
31. Luqmani YA, Schoenfeld A, Coombes RC. Detection of breast cancer micrometastases in axillary lymph nodes using polymerase chain reaction. Proc Annu Meet Am Assoc Cancer Res 1995;36:A1260.
32. Hayes DF, Bast RC, Desch CE, et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88: 1456-66.
33. Huvos AG, Hutter RVP, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44-46.
34. Butcher HR. Radical mastectomy for mammary carcinoma. Ann Surg 1969;170:833-84.
35. Bucalossi P, Veronesi U, Zingo L, et al. Enlarged mastectomy for breast cancer: review of 1213 cases. Am J Roentgenol Radium Ther Nucl Med 1971;111:119-22.
36. Schottenfeld D, Nash AG, Robbins GF, et al. Ten-year results of the treatment of primary operable breast carcinoma. Cancer 1976;38:1001-7.
37. Haagensen CD. Diseases of the breast. Philadelphia: W.B. Saunders, 1986.
38. Rosen PP, Oberman HA. Axillary lymph nodes. In: Rosen PP, Oberman HA, eds. Tumors of the mammary gland. Washington, DC: AFIP, 1993:380-83.
39. Page DL, Anderson TJ. Metastasis of breast cancer. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987:321-29.
40. Ridolfi RL, Rosen PP, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 1977;39:2280-85.
41. Turner DR, Millis RR. Breast tissue inclusions in axillary lymph nodes. Histopathology 1980;4:631-36.
42. Walker AN, Fechner RE. Papillary carcinoma arising from ectopic breast tissue in an axillary lymph node. Diagn Gynecol Obstet 1982;4:141-45.
43. Durkin K, Haagensen CD. An improved technique for the study of lymph nodes in surgical specimens. Ann Surg 1980;191:419-29.
44. Fisher B, Slack N. Number of nodes examined in the prognosis of breast carcinoma. Surg Gynecol Obstet 1970; 131:79-88.
45. Morrow M, Evans J, Rosen PP, Kinne DW. Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma? Cancer 1984;53:1329-32.
46. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
47. Epstein RJ. Routine or delayed axillary dissection for primary breast cancer? Eur J Cancer 1995;31A:1570-73.
48. Attiyeh FF, Jensen M, Huvos AG, Fracchia A. Axillary micrometastasis and macrometastasis in carcinoma of the breast. Surg Gynecol Obstet 1977;144:839-42.
49. Fisher ER, Palekar A, Rockette H, Redmand C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4) V. Significance of axillary nodal micro- and macrometastases. Cancer 1978;42:2032-38.
50. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer. Ann Surg 1981;194:585-91.
51. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 1993; 71:1780-90.
52. Neville MA. Are breast cancer axillary node micrometastases worth detecting? J Pathol 1990;161:283-84.
53. Neville MA. Breast cancer micrometastases in lymph nodes and bone marrow are prognostically important. Ann Oncol 1991;2:13-14.
54. Cote RJ, Taylor CR. Tumors of the breast. In: Taylor CR, Cote RJ, eds. Immunomicroscopy: a diagnostic tool for the surgical pathologist. Philadelphia: W.B. Saunders, 1994: 200-235.
55. Moreno JG, Croce CM, Fisher R, Monne M, Vihko P, Mulholland SG. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;52:6110-12.
56. Mattano LA, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by reverse transcriptase-polymerase chain reaction. Cancer Res 1992;52: 4701-5.
57. Hoon DSB, Doi F, Giuliano AE, Schmid P, Conrad AJ. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1995;76:533-35.
58. Morton D, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392.
59. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel node in breast cancer using a gamma probe. Surg Oncol 1993;2:335.
60. Giuliano AE, Kirgen DM, Guenther JM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391.
61. Giulano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15: 2345-50.
62. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818.
63. National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program. Summary of sentinel lymph nodes in breast cancer and melanoma strategy meeting. Rockville, MD: National Institutes of Health, 1997.
64. Giuliano AE, Dale P, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-401.